リラグルチドの世界市場レポート 2025年

リラグルチド市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6%で96億6,000万米ドルに成長します。予測期間の成長は、保険・償還政策の増加、ヘルスケアインフラ開発、認知度・教育イニシアチブの増加、高齢化人口の増加、糖尿病有病率の増加などに起因すると考えられます。予測期間における主な動向としては、人工知能や機械学習の利用、ウェアラブル技術への需要、持続的グルコースモニタリングの統合、バイオテクノロジーの進歩、デジタルヘルスプラットフォームの開発などが挙げられます。

糖尿病人口の増加は、今後数年間のリラグルチド市場の拡大を促進すると予測されます。糖尿病は、インスリンの分泌が不十分であったり、インスリンの利用が効率的でなかったりするために、身体が血糖値を効果的に調整するのに苦労する長期的な状態です。糖尿病の有病率は、座りがちなライフスタイル、食生活の乱れ、世界の肥満率の増加などの要因によって上昇しています。リラグルチドのような糖尿病治療薬は、インスリン分泌を促進し、血糖値を下げ、体重減少をサポートするホルモンGLP-1の作用を模倣することにより、2型糖尿病の管理を支援します。例えば、2024年3月、英国政府の報告書によると、2023年3月、イングランドで1型糖尿病の患者がNDAの参加GP診療所で8つのケアプロセスすべてを受けている割合は、前年の35.2％から43.8％に上昇しました。したがって、糖尿病人口の増加がリラグルチド市場の成長を牽引しています。

リラグルチド市場の主要企業は、ジェネリックGLP-1のような革新的な製品を生み出し、治療の選択肢を広げ、より手頃な代替品への需要に応えています。ジェネリックGLP-1とは、GLP-1受容体作動薬の先発品の特許が切れた後に製造されるもので、2型糖尿病や肥満症などの治療に費用対効果の高い選択肢を提供します。例えば、イスラエルに本社を置く製薬会社テバ・ファーマシューティカル・インダストリーズ社は、2024年6月、ビクトーザに類似した初のGLP-1ジェネリック医薬品を米国市場で発売し、こうした治療に対するニーズの高まりに対応しています。リラグルチド注射剤は、10歳以上の2型糖尿病の成人および小児の血糖管理の改善、ならびに2型糖尿病および既存の心血管疾患を有する成人の心血管イベントリスクの低減を目的として処方されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リラグルチド PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリラグルチド市場：成長率分析
• 世界のリラグルチド市場の実績：規模と成長, 2019-2024
• 世界のリラグルチド市場の予測：規模と成長, 2024-2029, 2034F
• 世界リラグルチド総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリラグルチド市場ブランド別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヴィクトザ
• サクセンダ
• 世界のリラグルチド市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局とドラッグストア
• オンライン薬局
• 世界のリラグルチド市場アプリケーションの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖尿病治療
• 体重管理
• 世界のリラグルチド市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 在宅ケア設定
• 世界のリラグルチド市場、タイプ別ビクトーザのサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2型糖尿病の治療
• 体重管理
• 世界のリラグルチド市場、サクセンダのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 減量治療
• 肥満管理

第7章 地域別・国別分析

• 世界のリラグルチド市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリラグルチド市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リラグルチド市場：競合情勢
• リラグルチド市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Limited
• Hanmi Pharmaceutical Co. Ltd.
• Intarcia Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リラグルチド市場2029：新たな機会を提供する国
• リラグルチド市場2029：新たな機会を提供するセグメント
• リラグルチド市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Liraglutide is a GLP-1 receptor agonist utilized for managing type 2 diabetes and obesity. It lowers blood sugar levels and encourages weight loss by imitating the incretin hormone GLP-1. Given through subcutaneous injection, it boosts insulin secretion and curbs appetite. Liraglutide is available under the brand names Victoza for diabetes and Saxenda for obesity.

The primary brands of liraglutide are Victoza and Saxenda. Victoza is a brand name for liraglutide, a medication prescribed for type 2 diabetes. It can be obtained from hospital pharmacies, retail pharmacies, drug stores, and online pharmacies, and is used for managing diabetes and weight. It is utilized by different end-users, such as hospitals, clinics, and home care settings.

The liraglutide market research report is one of a series of new reports from The Business Research Company that provides liraglutide market statistics, including liraglutide industry global market size, regional shares, competitors with a liraglutide market share, detailed liraglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide industry. This liraglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liraglutide market size has grown strongly in recent years. It will grow from $6.38 billion in 2024 to $6.95 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the increasing number of people diagnosed with type 2 diabetes, growing obesity rates, extensive clinical trials, growing awareness of diabetes complications, and rising innovations in drug delivery systems.

The liraglutide market size is expected to see strong growth in the next few years. It will grow to $9.66 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing insurance and reimbursement policies, healthcare infrastructure development, increasing awareness and educational initiatives, a growing aging population, and the increasing prevalence of diabetes. Major trends in the forecast period include the use of artificial intelligence and machine learning, demand for wearable technology, continuous glucose monitoring integration, biotechnology advancements, and the development of digital health platforms.

The growing diabetic population is anticipated to drive the expansion of the liraglutide market in the coming years. Diabetes is a long-term condition in which the body struggles to regulate blood sugar levels effectively, either due to inadequate insulin production or ineffective insulin utilization. The prevalence of diabetes is rising due to factors such as sedentary lifestyles, poor dietary habits, and increasing obesity rates globally. Diabetes medications like liraglutide aid in managing type 2 diabetes by mimicking the effects of the hormone GLP-1, which enhances insulin release, reduces blood sugar levels, and supports weight loss. For example, in March 2024, a report by the Government of the United Kingdom indicated that in March 2023, the proportion of individuals with type 1 diabetes in England receiving all 8 care processes at participating GP practices in the NDA rose to 43.8%, up from 35.2% the previous year. Therefore, the rising diabetic population is driving the growth of the liraglutide market.

Leading companies in the liraglutide market are creating innovative products, such as generic GLP-1, to broaden treatment options and meet the demand for more affordable alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists produced after the original branded medications' patent protection has expired, providing cost-effective options for treating conditions such as type 2 diabetes and obesity. For example, in June 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1 similar to Victoza in the U.S. market, addressing the growing need for these therapies. Liraglutide injections are prescribed to improve blood sugar management in adults and children aged 10 and older with type 2 diabetes and to reduce the risk of cardiovascular events in adults with type 2 diabetes and existing cardiovascular conditions.

In October 2023, Biocon Limited, a biopharmaceutical company based in India, entered into a partnership with Juno Pharmaceuticals to commercialize its vertically integrated, complex formulation, Liraglutide. According to the terms of the agreement, Biocon will handle the regulatory approval process for Liraglutide and will subsequently manage the manufacturing and supply of the product in the Canadian market. Juno Pharmaceuticals, a Canada-based pharmaceutical company, specializes in introducing complex and high-value generic and biosimilar products to the market.

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liraglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liraglutide market consists of sales of insulin products, weight management supplements, nutritional supplements, and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liraglutide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liraglutide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liraglutide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liraglutide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Brands: Victoza; Saxenda
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies And Drug Stores; Online Pharmacies
• 3) By Type Of Application: Diabetes Treatment; Weight Management
• 4) By End-Users: Hospitals And Clinics; Homecare Settings
• Subsegments:
• 1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
• 2) By Saxenda: Weight Loss Treatment Or Obesity Management
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liraglutide Market Characteristics

3. Liraglutide Market Trends And Strategies

4. Liraglutide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Liraglutide Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liraglutide PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liraglutide Market Growth Rate Analysis
• 5.4. Global Liraglutide Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liraglutide Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liraglutide Total Addressable Market (TAM)

6. Liraglutide Market Segmentation

• 6.1. Global Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Victoza
• Saxenda
• 6.2. Global Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies And Drug Stores
• Online Pharmacies
• 6.3. Global Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetes Treatment
• Weight Management
• 6.4. Global Liraglutide Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Homecare Settings
• 6.5. Global Liraglutide Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetes Treatment
• Weight Management
• 6.6. Global Liraglutide Market, Sub-Segmentation Of Saxenda, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Weight Loss Treatment
• Obesity Management

7. Liraglutide Market Regional And Country Analysis

• 7.1. Global Liraglutide Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liraglutide Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liraglutide Market

• 8.1. Asia-Pacific Liraglutide Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liraglutide Market

• 9.1. China Liraglutide Market Overview
• 9.2. China Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liraglutide Market

• 10.1. India Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liraglutide Market

• 11.1. Japan Liraglutide Market Overview
• 11.2. Japan Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liraglutide Market

• 12.1. Australia Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liraglutide Market

• 13.1. Indonesia Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liraglutide Market

• 14.1. South Korea Liraglutide Market Overview
• 14.2. South Korea Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liraglutide Market

• 15.1. Western Europe Liraglutide Market Overview
• 15.2. Western Europe Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liraglutide Market

• 16.1. UK Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liraglutide Market

• 17.1. Germany Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liraglutide Market

• 18.1. France Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liraglutide Market

• 19.1. Italy Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liraglutide Market

• 20.1. Spain Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liraglutide Market

• 21.1. Eastern Europe Liraglutide Market Overview
• 21.2. Eastern Europe Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liraglutide Market

• 22.1. Russia Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liraglutide Market

• 23.1. North America Liraglutide Market Overview
• 23.2. North America Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liraglutide Market

• 24.1. USA Liraglutide Market Overview
• 24.2. USA Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liraglutide Market

• 25.1. Canada Liraglutide Market Overview
• 25.2. Canada Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liraglutide Market

• 26.1. South America Liraglutide Market Overview
• 26.2. South America Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liraglutide Market

• 27.1. Brazil Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liraglutide Market

• 28.1. Middle East Liraglutide Market Overview
• 28.2. Middle East Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liraglutide Market

• 29.1. Africa Liraglutide Market Overview
• 29.2. Africa Liraglutide Market, Segmentation By Brands, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liraglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liraglutide Market, Segmentation By Type Of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liraglutide Market Competitive Landscape And Company Profiles

• 30.1. Liraglutide Market Competitive Landscape
• 30.2. Liraglutide Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Liraglutide Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Novartis International AG
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. GlaxoSmithKline Plc
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Novo Nordisk A/S
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Cipla Limited
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Biocon Limited
• 31.14. Hanmi Pharmaceutical Co. Ltd.
• 31.15. Intarcia Therapeutics Inc.

32. Global Liraglutide Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liraglutide Market

34. Recent Developments In The Liraglutide Market

35. Liraglutide Market High Potential Countries, Segments and Strategies

• 35.1 Liraglutide Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liraglutide Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liraglutide Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer